Journal of Applied Data Analysis and Modern Stochastic Modelling **DOI: 10.67274/JADAMSM.3-1-2**
Vol. 3 No. 1 (June, 2026)

ARTIFICIAL INTELLIGENCE IN MEDICINE: PROSPECTS AND APPLICATIONS IN UROLOGY

ILOLOV A.M., MAKHMADAMINOVA M.M., MUKHUDDINOV A.K., AND MUSTAFAKULOV S.S.

Abstract. This paper presents a systematic analysis of contemporary directions in the application of artificial intelligence (AI) technologies to urological practice and pharmaceutical research. The principal domains of intelligent-algorithm deployment are examined, encompassing automated medical image analysis, the development of predictive models based on machine learning methods, the utilisation of robotic surgical systems, and the integration of digital platforms for remote patient monitoring. Particular attention is paid to the role of hybrid neuro-fuzzy architectures such as ANFIS in clinical decision support and to the ethical and regulatory challenges accompanying the adoption of AI in healthcare. The study evaluates the current state and future prospects of AI-driven approaches in urology and highlights their potential to enhance diagnostic accuracy, optimise therapeutic decision-making, and improve patient outcomes.

1. Introduction

Over the past two decades, the rapid advancement of digital technologies and information systems has fundamentally transformed approaches to the organisation of medical care, disease diagnosis, and the development of treatment modalities [1, 2, 3]. The digitisation of healthcare has become one of the key directions in the modernisation of medical science and practice. In this context, the integration of artificial intelligence (AI) technologies acquires particular significance, as it opens new possibilities for the processing and analysis of medical information, enhancement of diagnostic accuracy, and improvement of clinical decision quality [2, 3, 6].

Artificial intelligence constitutes a set of algorithms and computational methods that enable computer systems to analyse large volumes of data, detect latent patterns, and generate decisions approaching the quality of expert judgements [2, 3, 6]. Contemporary AI methods include machine learning, deep neural networks, natural language processing, and intelligent data-mining techniques [7, 12, 13]. The

Date: Date of Submission February 27, 2026; Date of Acceptance March 16, 2026, Communicated by Mamadsho Ilolov.

2000 *Mathematics Subject Classification.* Primary 35A09; Secondary 35B36.

Key words and phrases. artificial intelligence, urology, machine learning, medical diagnostics, medical image analysis, robotic surgery, pharmaceutical research, medical data.

application of these technologies makes it possible to automate complex analytical processes, improve the efficiency of information processing, and minimise the influence of the human factor in the interpretation of research results.

Modern medicine is characterised by the rapid growth of generated data volumes [6, 13]. The principal sources of medical information include the results of diagnostic imaging, laboratory tests, genomic data, electronic health records, remote patient monitoring data, and information obtained in the course of clinical trials. As medical technologies advance, the volume and complexity of such data continue to increase, necessitating new methods of analysis and interpretation. Traditional statistical approaches prove insufficient for the analysis of high-dimensional datasets, which underscores the role of machine learning and deep neural networks [7, 14, 20].

One domain in which AI demonstrates especially high potential is urology [5, 12, 27]. Urological disorders occupy a prominent place in the overall disease burden of the population and are characterised by high prevalence across all age groups. Many urological pathologies follow a chronic course, requiring long-term surveillance, comprehensive diagnostics, and an individualised therapeutic approach [27, 26].

Urological diagnosis frequently involves a range of instrumental and laboratory examinations, including ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic procedures, and the analysis of laboratory and clinical indicators. Interpretation of these findings demands high specialist qualifications and considerable time. In this context, AI technologies can substantially enhance the efficiency of the diagnostic process, improve the accuracy of pathological-change detection, and accelerate the processing of medical information.

Common urological conditions include prostate cancer, bladder cancer, urolithiasis, chronic kidney disease, urinary tract infections, and various voiding dysfunction disorders. Many of these conditions present with a complex clinical picture and require early diagnosis to prevent complications and improve treatment prognosis.

The application of AI in urology opens wide prospects for improving healthcare quality. Machine learning algorithms can be applied to medical image analysis, the detection of early signs of oncological disease, the prediction of pathological progression, and the development of individualised treatment strategies [7, 11]. Furthermore, the introduction of intelligent systems allows automation of several diagnostic and analytical processes, thereby reducing the workload on medical personnel and enhancing the operational efficiency of healthcare institutions.

In recent years, considerable attention has been devoted to the development of clinical decision-support systems based on AI technologies. Such systems are capable of analysing large quantities of clinical data and providing physicians with supplementary recommendations when selecting treatment strategies. In addition, AI is actively deployed in robotic surgery, telemedicine systems, and remote patient monitoring, thus broadening the capabilities of modern medical practice [12, 18, 19].

Despite its significant advantages, the integration of AI into medical practice raises a range of scientific, technological, and ethical questions. Issues of particular importance include the standardisation of algorithms, the security of medical data, the protection of patient personal information, and the integration of intelligent systems into existing healthcare infrastructure [8, 19, 32].

The aim of this paper is to analyse contemporary directions of AI application in urology and to evaluate the prospects for the development of these technologies in clinical practice.

2. Artificial Intelligence and Machine Learning in Medicine

Artificial intelligence in medicine represents a complex of modern computational technologies aimed at analysing medical data, detecting latent patterns, and supporting clinical decision-making [2, 3, 12]. In recent years, advances in information technology, the growth of medical data volumes, and the improvement of computational capacity have promoted the active integration of intelligent algorithms across various domains of healthcare. AI application makes it possible to substantially enhance diagnostic efficiency, improve disease-course prediction, and optimise the selection of therapeutic strategies.

One of the most widespread directions of AI is *machine learning* (ML). This approach involves the creation of algorithms capable of learning from data analysis without requiring explicit step-by-step programming of each computational procedure. Machine learning allows the detection of complex interrelationships among various parameters and the use of these patterns for the construction of predictive models [12, 13].

The scientific literature distinguishes several principal types of machine learning [13]. Hybrid systems such as ANFIS (Adaptive Neuro-Fuzzy Inference System) combine neural networks with fuzzy logic, enabling effective modelling of complex medical processes and decision-making under conditions of uncertainty [9, 35, 34].

Supervised learning relies on labelled datasets in which each observation corresponds to a defined outcome or category. Algorithms trained on such data can subsequently be used for the classification of new observations or the prediction of various indicators. In medicine, this approach is widely employed for disease diagnosis, the interpretation of medical images, and the assessment of the risk of developing pathological conditions.

Unsupervised learning is applied to the analysis of unlabelled data. Algorithms detect hidden structures, group objects by similarity, and identify patterns that may not be apparent through conventional statistical analysis. In medical research, such methods are used for identifying novel clinical subtypes of disease, analysing genomic data, and studying complex biological processes.

Reinforcement learning is a method in which a system interacts with its environment and receives feedback in the form of reward or penalty for performed actions. This approach is applied in the development of intelligent control systems, including robotic surgical technologies and automated clinical decision-support systems.

Another important direction is *deep learning*, based on multi-layer neural networks. Deep neural networks are capable of effectively analysing complex high-dimensional data, including medical images, biosignals, and textual information.

By virtue of their ability to extract features automatically from raw data, deep learning methods are widely applied to the analysis of MRI, CT, ultrasound, and other types of medical imaging.

In recent years, *large language models* (LLMs) based on transformer architecture have also experienced significant development. These models are capable of analysing vast arrays of textual information, including scientific medical literature, clinical guidelines, and electronic health records. The use of such systems makes it possible to automate the preparation of medical reports, facilitate information retrieval, and provide physicians with decision-support assistance.

The principal areas of AI application in medicine include:

- diagnosis of various diseases;
- prediction of pathological processes;
- clinical decision-support systems;
- medical image analysis;
- robotic surgery;
- development of personalised treatment approaches.

Collectively, these technologies form the foundation for the development of digital medicine, which aims to improve healthcare quality and to optimise the performance of the healthcare system.

3. Artificial Intelligence in the Diagnosis of Urological Diseases

One of the most actively developing fields of AI application is the diagnosis of urological diseases. Urological pathologies are characterised by high prevalence and frequently require a comprehensive diagnostic approach encompassing imaging methods, laboratory tests, and clinical assessment. Modern AI algorithms are capable of analysing medical images, detecting pathological changes at early disease stages, and assisting physicians in the interpretation of diagnostic data. The use of such technologies makes it possible to improve diagnostic accuracy, reduce the time required for analysis, and decrease the probability of diagnostic errors [5, 12].

3.1. Prostate Cancer Diagnosis. Prostate cancer is one of the most prevalent malignant diseases in men and occupies a prominent place in the overall oncological disease burden. Early diagnosis plays a key role in improving the effectiveness of treatment and enhancing the patient prognosis.

Conventional diagnostic methods include serum prostate-specific antigen (PSA) assay, prostate MRI, and biopsy. However, the interpretation of these findings may be complex and demands a high level of specialist expertise.

AI algorithms are capable of analysing prostate MRI images and identifying suspicious tissue regions with high accuracy. The use of deep neural networks enables the automatic recognition of structural tissue abnormalities and the assessment of the likelihood of a malignant process [12, 11, 16].

Studies demonstrate that the application of ML algorithms can increase the sensitivity of prostate cancer diagnosis and reduce the number of unnecessary biopsies. Furthermore, AI systems are employed for the automatic segmentation of the prostate gland on medical images, facilitating the planning of surgical interventions and radiotherapy.

3.2. Bladder Cancer Diagnosis. Bladder cancer is one of the most common malignant tumours of the urinary tract. The primary diagnostic method remains cystoscopy, which allows visual assessment of the bladder mucosa.

Interpretation of cystoscopic images is, however, substantially dependent on the physician's experience and may be subject to subjective error. The use of computer vision algorithms makes it possible to automate image analysis and improve the accuracy of tumour-change detection [5].

Modern AI systems are capable of analysing cystoscopy video streams, highlighting suspicious mucosal areas, and performing tumour segmentation. Some algorithms also enable tumour grading according to degree of malignancy, which may contribute to more precise treatment planning.

3.3. Renal Disease Diagnosis. Artificial intelligence is actively applied to the analysis of CT and ultrasound examinations of the kidneys. Machine learning algorithms allow the detection of various pathological changes, including cysts, tumours, inflammatory processes, and structural anomalies.

Beyond image analysis, intelligent systems may be used for processing laboratory data [11]. Based on the analysis of clinical indicators such as serum creatinine, glomerular filtration rate (GFR), and other biochemical parameters, algorithms are capable of predicting the risk of chronic kidney disease development and assessing the likelihood of disease progression.

4. Predictive Models in Urology

One of the most promising directions of AI application is the creation of predictive models that allow the estimation of the probability of developing various diseases and complications [17, 33]. Predictive algorithms are capable of analysing large numbers of clinical parameters and identifying factors that influence the course of a pathological process.

In urology, such models may be used for predicting the risk of oncological recurrence, assessing the likelihood of disease progression, and selecting the optimal therapeutic strategy.

For example, machine learning algorithms can be applied to predict the risk of renal cancer recurrence following surgical treatment. Such models incorporate numerous clinical factors, including patient age, disease stage, histopathological findings, tumour size, and the presence of comorbidities.

Predictive systems are also employed for assessing the risk of urolithiasis and the probability of recurrent stone formation. Analysis of clinical and biochemical data allows identification of patients at high risk of recurrence and the development of individualised preventive measures.

The use of fuzzy modelling methods and stochastic differential equations provides an additional mathematical framework for constructing predictive models that account for uncertainty and inter-individual variability in medical data [34, 33].

5. Robotic Surgery

Modern robotic surgical systems play an increasingly important role in urological practice. The utilisation of robotic technologies substantially increases surgical precision, reduces operative trauma, and improves postoperative outcomes.

One of the most widely known robotic systems is the da Vinci surgical platform, which is extensively used for radical prostatectomy, nephrectomy, and other urological procedures.

The integration of AI algorithms into robotic systems opens new possibilities for improving the efficiency of surgical interventions. Machine learning algorithms are capable of analysing data from previous operations and helping the surgeon optimise instrument trajectories.

Furthermore, intelligent systems may be used for predicting the risk of complications, estimating the duration of surgery, and planning surgical tactics.

In future, it may become feasible to create partially autonomous surgical systems capable of performing specific operative stages under physician supervision.

6. Telemedicine and Remote Patient Monitoring

Telemedicine is becoming an important instrument for the follow-up of patients with chronic urological conditions. The development of mobile technologies and wearable devices enables continuous monitoring of patient status and real-time acquisition of medical data. Wearable sensors, mobile applications, and digital healthcare platforms allow the collection of data on various physiological parameters, including voiding frequency, urinary output, physical activity indicators, and other characteristics of physiological state.

AI algorithms can analyse remote monitoring data and detect early signs of patient deterioration [18]. For example, changes in voiding parameters may indicate the development of a urinary tract infection or exacerbation of a chronic condition.

The use of such systems makes it possible to improve complications prophylaxis, reduce the number of hospitalisations, and enhance patient quality of life.

7. Ethical and Legal Aspects of AI Application

Despite the significant advantages of AI in medicine, the implementation of these technologies is accompanied by a range of serious ethical and legal questions. One of the key issues concerns the attribution of responsibility for decisions made by AI algorithms. In the event of a diagnostic error, the question arises as to who bears liability for the consequences: the software developer, the medical institution, or the physician using the system. Another important challenge is the protection of personal medical data. Medical information belongs to the category of particularly sensitive data and requires rigorous security measures for its storage and processing.

Additionally, there is the problem of *algorithmic bias*, which may arise when limited or insufficiently representative training datasets are used. In such cases, algorithms may exhibit reduced accuracy when applied to certain patient groups [8, 19, 32].

These issues underscore the necessity of developing robust regulatory frameworks, ethical standards, and transparent evaluation criteria for AI systems deployed in clinical settings. Interdisciplinary collaboration among specialists in medicine, information technology, and biomedical research is essential for addressing these challenges.

8. Prospects for the Development of Artificial Intelligence in Urology

The advancement of AI technologies opens wide prospects for the further improvement of urological practice. In the coming years, a substantial expansion of intelligent-system application across various directions of medical activity is anticipated.

The most promising directions include:

- early diagnosis of malignant diseases;
- development of personalised medicine;
- integration of genomic data into clinical decision-making;
- creation of intelligent physician-support systems;
- automation of medical image analysis.

Over the longer term, it may become possible to create comprehensive digital healthcare ecosystems in which AI is integrated at every stage of healthcare delivery—from prevention and early diagnosis through to treatment and patient rehabilitation [13, 33]. Recent work on AI applications in multisectoral domains—including tourism and infrastructure management—also demonstrates the broad transferability of fuzzy modelling and intelligent-decision frameworks to complex sociotechnical systems, which is of direct relevance to the design of integrated healthcare platforms [36].

9. Application of Artificial Intelligence to Drug Synthesis and Discovery

A separate and promising direction of medical AI concerns the application of machine learning algorithms to the development and synthesis of novel pharmaceutical agents. The conventional drug-development process is protracted and complex, typically requiring from ten to fifteen years and substantial financial investment.

The fundamental difficulty lies in the need to analyse an enormous number of chemical compounds and their interactions with biological targets. Only a small fraction of candidate molecules successfully pass all stages of preclinical and clinical investigation.

Modern AI systems can substantially accelerate this process. Deep learning algorithms are capable of analysing chemical databases, predicting molecular structures, and modelling their interactions with proteins, enzymes, and cellular receptors [9, 35].

The use of computational chemistry methods and generative models allows the virtual screening of millions of candidate compounds prior to the commencement of laboratory experiments. This significantly reduces the time and resource expenditure required for new drug development.

Such technologies have direct applications in urology—for example, AI algorithms may be used for the development of novel agents targeting prostate cancer, more effective treatments for urinary tract infections, or drugs promoting the dissolution of urinary calculi.

Thus, the integration of AI technologies into pharmaceutical research opens new possibilities for the accelerated creation of therapeutic agents and the enhancement of medical-research effectiveness.

Conclusion

Artificial intelligence is currently emerging as one of the key factors in the transformation of modern medicine and healthcare as a whole. The development of digital technologies, the growth of medical data volumes, and the advancement of data-processing methods create favourable conditions for the active introduction of intelligent algorithms into clinical practice. AI application opens new possibilities for improving diagnostic accuracy, enhancing disease-course prediction, and optimising therapeutic interventions.

The analysis conducted demonstrates that, in the field of urology, AI technologies already exhibit substantial advantages. The application of machine learning algorithms and deep neural networks enables effective analysis of medical images, early detection of pathological changes, and improved accuracy in the diagnosis of urological pathologies. These technologies are of particular importance in the detection of urogenital malignancies, including prostate and bladder cancer, where timely diagnosis plays a critical role in treatment success.

In addition, intelligent algorithms are actively employed for the creation of predictive models that allow estimation of the probability of complications, disease recurrence, and pathological-process progression. The use of such systems facilitates more precise planning of therapeutic tactics and the formation of an individualised approach to patient management.

An important direction of modern medical-technology development is also the integration of AI into robotic surgery. Intelligent systems make it possible to improve surgical precision, reduce the risk of postoperative complications, and enhance the functional outcomes of patient treatment. Further opportunities are provided by the development of telemedicine and remote monitoring systems, which allow continuous patient surveillance and timely identification of signs of clinical deterioration.

Nevertheless, the integration of AI into medical practice is accompanied by a range of technological, organisational, and ethical questions. The most significant challenges include the security and confidentiality of medical data, the standardisation of algorithms, and the attribution of responsibility for decisions made by intelligent systems. Addressing these issues requires the further development of regulatory and legal frameworks, as well as interdisciplinary collaboration among specialists in medicine, information technology, and biomedical research.

Despite existing limitations, the prospects for AI development in medicine appear highly significant. It is anticipated that further improvements in machine learning algorithms, broader availability of large-scale medical data, and development of digital healthcare infrastructure will promote wider integration of intelligent technologies into clinical practice.

Thus, artificial intelligence possesses substantial potential for improving the effectiveness of medical care, enhancing the quality of diagnosis and treatment, and raising patient safety standards. In the long term, the integration of intelligent technologies into the healthcare system may fundamentally transform approaches to the organisation of medical care and contribute to the development of a more effective, personalised, and evidence-based medicine.

References

[1] Topol E. J. High-performance medicine: the convergence of human and artificial intelligence. *Nature Medicine*, 2021, vol. 27, pp. 44–56.

[2] Esteva A., Robicquet A., Ramsundar B. et al. A guide to deep learning in healthcare. *Nature Medicine*, 2021, vol. 27, no. 2, pp. 215–229.

[3] Jiang F., Jiang Y., Zhi H. et al. Artificial intelligence in healthcare: past, present and future. *Stroke and Vascular Neurology*, 2021, vol. 6, no. 2, pp. 230–243.

[4] Ting D. S., Pasquale L. R., Peng L. et al. Artificial intelligence and deep learning in medical imaging. *The Lancet Digital Health*, 2022, vol. 4, no. 2, pp. 134–148.

[5] Rundo L., Han C., Nagano Y. et al. Use of artificial intelligence in urology: current clinical applications and future perspectives. *Nature Reviews Urology*, 2022, vol. 19, pp. 402–419.

[6] Rajpurkar P., Chen E., Banerjee O., Topol E. AI in health and medicine. *Nature Medicine*, 2022, vol. 28, pp. 31–38.

[7] He K., Zhang X., Ren S., Sun J. Deep learning for medical image analysis. *IEEE Transactions on Medical Imaging*, 2022, vol. 41, no. 6, pp. 1439–1456.

[8] Kelly C. J., Karthikesalingam A., Suleyman M., Corrado G. Key challenges for delivering clinical impact with artificial intelligence. *The Lancet Digital Health*, 2023, vol. 5, no. 4, pp. 231–238.

[9] Ilolov M., Rakhmatov J., Kabirov S., Inagaki F. Maximum power point tracking using adaptive neuro-fuzzy inference systems for photovoltaic modules. *Global and Stochastic Analysis*, 2024, pp. 1–10.

[10] Haider M. A., Van der Kwast T., Tanguay J. Artificial intelligence in prostate cancer imaging. *European Urology*, 2023, vol. 83, no. 2, pp. 165–177.

[11] McKinney S. M., Sieniek M., Godbole V. et al. International evaluation of an AI system for cancer screening. *Nature*, 2023, vol. 577, pp. 89–94.

[12] Liao Z., Ding H., Zhang Y. Artificial intelligence for kidney disease detection and prediction. *Kidney International Reports*, 2023, vol. 8, no. 3, pp. 456–468.

[13] Rajkomar A., Dean J., Kohane I. Machine learning in medicine. *New England Journal of Medicine*, 2024, vol. 390, pp. 1347–1358.

[14] Yu K. H., Beam A. L., Kohane I. Artificial intelligence in healthcare. *Nature Biomedical Engineering*, 2024, vol. 8, pp. 1–10.

[15] Erickson B. J., Korfiatis P., Akkus Z. Machine learning for medical imaging. *Radiographics*, 2024, vol. 44, no. 2, pp. 305–320.

[16] Davenport T., Kalakota R. The potential for artificial intelligence in healthcare. *Future Healthcare Journal*, 2024, vol. 11, no. 1, pp. 25–31.

[17] Heidenreich A., Bastian P. J., Bellmunt J. et al. EAU guidelines on prostate cancer. *European Urology*, 2024, vol. 85, pp. 65–79.

[18] Wiggins B., Smith M. Artificial intelligence in robotic surgery. *Journal of Robotic Surgery*, 2025, vol. 19, pp. 101–112.

[19] Liu X., Rivera S. C., Moher D. Reporting guidelines for clinical trials involving AI interventions. *BMJ*, 2025, vol. 370, m3164.

[20] Patel V. L., Shortliffe E. H. Artificial intelligence in clinical decision support systems. *Journal of Biomedical Informatics*, 2025, vol. 132, 104122.

[21] Wang S., Summers R. M. Machine learning and radiology: applications and future directions. *Radiology*, 2025, vol. 305, no. 1, pp. 12–24.
[22] Chen J., Huang Y., Li X. Artificial intelligence driven drug discovery. *Drug Discovery Today*, 2026, vol. 31, no. 2, pp. 450–461.
[23] Brown N., Fiscato M., Segler M. Artificial intelligence in chemical synthesis planning. *Nature Communications*, 2026, vol. 17, 1123.
[24] Topol E. Deep medicine and the future of healthcare. *The Lancet*, 2026, vol. 407, pp. 1200–1205.
[25] Kaprin A. D., Apolikhin O. I. Current trends in urology development [in Russian]. *Urologiia*, 2021, no. 3, pp. 5–12.
[26] Apolikhin O. I., Sivkov A. V. Digital technologies in urology [in Russian]. *Urologiia*, 2022, no. 4, pp. 8–15.
[27] Shlyakhto E. V., Konradi A. O. Artificial intelligence in medicine: opportunities and prospects [in Russian]. *Kardiologiia*, 2022, vol. 62, no. 5, pp. 4–10.
[28] Tyurin I. E., Morozov S. P. Artificial intelligence in diagnostic radiology [in Russian]. *Vestnik Rentgenologii i Radiologii*, 2023, no. 2, pp. 15–23.
[29] Sidorov P. I., Vasiliev S. V. Application of machine learning in clinical medicine [in Russian]. *Meditsinskaya Informatika*, 2024, no. 1, pp. 21–29.
[30] Gusev A. V., Kuznetsov P. P. Artificial intelligence and digital transformation of healthcare [in Russian]. *Management v Zdravookhranenii*, 2024, no. 3, pp. 12–18.
[31] Boytsov S. A., Samorodskaya I. V. Prospects for the application of artificial intelligence in clinical practice [in Russian]. *Terapevticheskiy Arkhiv*, 2025, vol. 97, no. 6, pp. 5–11.
[32] Ilolov M., Rakhmatov J. Sh., Karimova S. M., Bobozoda G. J. Pros and cons of artificial intelligence [in Russian]. In: *Proceedings of the International Conference "The Role of the Digital Economy in Accelerated Industrialisation"*. Khujand, 2025, pp. 9–18.
[33] Ilolov M., Kuchakshoev K., Mirshahi M., Rakhmatov J. Sh. Nonlinear stochastic equation in epidemiology. *Global and Stochastic Analysis*, 2023, vol. 10, no. 3, pp. 75–84.
[34] Rakhmatov J. Sh. Fuzzy differential equations: applications for analysing and predicting cyberattacks. *Journal of Applied Data Analysis and Modern Stochastic Modelling*, 2025, vol. 2, no. 2, pp. 53–58.
[35] Ilolov M., Kabirov Sh., Li P., Amonulloev A., Rasulov S., Ilolov A., Rakhmatov J. Sh. ANFIS model for fault diagnosis in photovoltaic systems. In: *Proceedings of the International Scientific Conference "Status and Prospects for the Development of Renewable Energy in Tajikistan"*, 23–25 June 2025, pp. 68–77.
[36] Rakhmatov J. Sh., Azizov R. O., Rasulov S. Use of artificial intelligence in the development of tourism services: fuzzy analysis models and current practices [in Russian]. *Scientific Journal "Water Resources, Energy and Ecology" of the Institute of Water Problems, Hydropower and Ecology of the National Academy of Sciences of Tajikistan*, 2026, vol. 6, no. 1, pp. 127–135.

Ilolov A.M.: International University of Tourism and Entrepreneurship of Tajikistan
Email address: ilolov2@gmail.com

Makhmadaminova M.M.: International University of Tourism and Entrepreneurship of Tajikistan

Mukhuddinov A.K.: International University of Tourism and Entrepreneurship of Tajikistan

Mustafakulov S.S.: International University of Tourism and Entrepreneurship of Tajikistan